公开(公告)号：US20230323475A1

公开(公告)日：2023-10-12

申请号：US18314267

申请日：2023-05-09

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Kana Sakamoto ,  Ryohei Katayama ,  Seiji Sakata

IPC: C12Q1/6886 ,  A61K31/167 ,  G01N33/50 ,  G01N33/48 ,  A61K31/551 ,  G01N33/574 ,  A61K31/4745 ,  A61K45/00 ,  C12Q1/68 ,  A61P35/02 ,  A61P43/00 ,  A61K31/4045 ,  A61K31/55 ,  A61K31/635 ,  A61K31/675

CPC classification number: C12Q1/6886 ,  A61K31/167 ,  G01N33/5023 ,  G01N33/48 ,  G01N33/5011 ,  G01N33/5047 ,  A61K31/551 ,  G01N33/57426 ,  A61K31/4745 ,  A61K45/00 ,  G01N33/5748 ,  C12Q1/68 ,  A61P35/02 ,  A61P43/00 ,  A61K31/4045 ,  A61K31/55 ,  A61K31/635 ,  A61K31/675 ,  G01N2333/82 ,  C12Q2600/158 ,  G01N2800/56 ,  C12Q2600/16

Abstract: The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.

公开(公告)号：US20190033293A1

公开(公告)日：2019-01-31

申请号：US16070110

申请日：2017-01-13

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: G01N33/50 ,  A61K38/00 ,  C12N15/62 ,  C12N9/12 ,  C12N9/88 ,  C12N15/113 ,  A61P35/00

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US10921311B2

公开(公告)日：2021-02-16

申请号：US16070110

申请日：2017-01-13

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: C07H21/04 ,  C12Q1/68 ,  G01N33/50 ,  C12N9/12 ,  G01N33/574 ,  C12N9/88 ,  C07K14/82 ,  A61K31/519 ,  A61P35/00 ,  A61K38/00 ,  C12N15/113 ,  C12N15/62 ,  C12Q1/6886 ,  C12Q1/6853 ,  C12Q1/686

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US12055538B2

公开(公告)日：2024-08-06

申请号：US17144776

申请日：2021-01-08

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: C07H21/04 ,  A61K31/519 ,  A61K38/00 ,  A61P35/00 ,  C07K14/82 ,  C12N9/12 ,  C12N9/88 ,  C12N15/113 ,  C12N15/62 ,  G01N33/50 ,  G01N33/574 ,  C12Q1/6853 ,  C12Q1/686 ,  C12Q1/6886

CPC classification number: G01N33/5011 ,  A61K31/519 ,  A61K38/005 ,  A61P35/00 ,  C07K14/82 ,  C12N9/12 ,  C12N9/88 ,  C12N15/113 ,  C12N15/62 ,  C12Y207/11025 ,  C12Y402/01047 ,  G01N33/57446 ,  C12Q1/6853 ,  C12Q1/686 ,  C12Q1/6886

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US20210140943A1

公开(公告)日：2021-05-13

申请号：US17144776

申请日：2021-01-08

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: G01N33/50 ,  C12N9/12 ,  G01N33/574 ,  C12N9/88 ,  C07K14/82 ,  A61K31/519 ,  A61P35/00 ,  A61K38/00 ,  C12N15/113 ,  C12N15/62

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US10705087B2

公开(公告)日：2020-07-07

申请号：US14907689

申请日：2014-07-25

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Yuki Togashi ,  Seiji Sakata ,  Satoko Baba

IPC: C12Q1/68 ,  G01N33/574 ,  C12Q1/6886 ,  G01N33/50 ,  A61K31/277 ,  A61K31/553

Abstract: A polynucleotide, which is a novel causative gene for cancer, is elucidated, and, based on this finding, provided are a method for detecting the polynucleotide, or a polypeptide encoded by the polynucleotide; a kit and a primer set for the detection; a method for screening an inhibitor of the polypeptide; and a pharmaceutical composition for treating a cancer containing the inhibitor. In the detection method of the present invention, an NTRK3 fusion protein, or a fusion gene encoding the fusion protein, or an ETV6 fusion protein, or a fusion gene encoding the fusion protein, in a sample derived from the digestive system obtained from a subject, is detected.